Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Cash from Investing Activities: 2020-2024

Historic Cash from Investing Activities for Prime Medicine (PRME) over the last 5 years, with Dec 2024 value amounting to $68.5 million.

  • Prime Medicine's Cash from Investing Activities fell 282.99% to -$92.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$88.8 million, marking a year-over-year decrease of 244.48%. This contributed to the annual value of $68.5 million for FY2024, which is 265.86% up from last year.
  • According to the latest figures from FY2024, Prime Medicine's Cash from Investing Activities is $68.5 million, which was up 265.86% from $18.7 million recorded in FY2023.
  • Prime Medicine's 5-year Cash from Investing Activities high stood at $68.5 million for FY2024, and its period low was -$73.6 million during FY2021.
  • For the 3-year period, Prime Medicine's Cash from Investing Activities averaged around $13.4 million, with its median value being $18.7 million (2023).
  • As far as peak fluctuations go, Prime Medicine's Cash from Investing Activities tumbled by 6,832.77% in 2021, and later skyrocketed by 265.86% in 2024.
  • Over the past 5 years, Prime Medicine's Cash from Investing Activities (Yearly) stood at -$1.1 million in 2020, then tumbled by 6,832.77% to -$73.6 million in 2021, then surged by 36.03% to -$47.1 million in 2022, then surged by 139.73% to $18.7 million in 2023, then soared by 265.86% to $68.5 million in 2024.